摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2'-O-{3-[(cyclobutylcarbonyl)amino]propyl}-9-deoxo-9a-methyl-9a-aza-9a-homoerythromycin A | 1236142-99-6

中文名称
——
中文别名
——
英文名称
2'-O-{3-[(cyclobutylcarbonyl)amino]propyl}-9-deoxo-9a-methyl-9a-aza-9a-homoerythromycin A
英文别名
N-[3-[(2S,3R,4S,6R)-4-(dimethylamino)-2-[[(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-2-ethyl-3,4,10-trihydroxy-13-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,6,8,10,12,14-heptamethyl-15-oxo-1-oxa-6-azacyclopentadec-11-yl]oxy]-6-methyloxan-3-yl]oxypropyl]cyclobutanecarboxamide
2'-O-{3-[(cyclobutylcarbonyl)amino]propyl}-9-deoxo-9a-methyl-9a-aza-9a-homoerythromycin A化学式
CAS
1236142-99-6
化学式
C46H85N3O13
mdl
——
分子量
888.193
InChiKey
FXRJNFVMSYRHKS-GCFGWCMVSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    5.2
  • 重原子数:
    62
  • 可旋转键数:
    13
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.96
  • 拓扑面积:
    198
  • 氢给体数:
    5
  • 氢受体数:
    15

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为产物:
    描述:
    环丁基甲酸2'-O-(3-aminopropyl)-9-deoxo-9a-methyl-9a-aza-9a-homoerythromycin A1-羟基苯并三唑 作用下, 以 二氯甲烷N,N-二甲基甲酰胺 为溶剂, 反应 0.08h, 以64.6%的产率得到2'-O-{3-[(cyclobutylcarbonyl)amino]propyl}-9-deoxo-9a-methyl-9a-aza-9a-homoerythromycin A
    参考文献:
    名称:
    大环内酯周围-大环3D结构对亲脂性和细胞积累的影响。
    摘要:
    这项研究的目的是在分子水平上研究合理设计的阿奇霉素和克拉霉素衍生物的亲脂性和细胞蓄积性。使用计算的结构参数以及实验确定的亲脂性,研究了取代位点和取代基性质对所研究化合物的整体物理化学特征和细胞积累的影响。在基于分子3D结构的计算机模型中,研究了构象效应对所研究性质的影响,并基于非经验参数预测了此类分子的亲脂性和细胞蓄积性。在验证和测试集上探索了开发模型的适用性,并与先前开发的经验模型进行了比较。
    DOI:
    10.1016/j.ejmech.2017.03.056
点击查看最新优质反应信息

文献信息

  • [EN] 9-DEOXO- 9A-METHYL- 9A- AZA- 9A-H0M0ERYTHR0MYCIN A DERIVATIVES FOR THE TREATMENT OF NEUTROPHIL DOMINATED INFLAMMATORY DISEASES<br/>[FR] DÉRIVÉS DE 9-DÉOXO-9A-MÉTHYL-9A-AZA-9A-HOMOÉRYTHROMYCINE A POUR LE TRAITEMENT DE MALADIES INFLAMMATOIRES DOMINÉES PAR LES NEUTROPHILES
    申请人:GLAXOSMITHKLINE ZAGREB
    公开号:WO2010086350A1
    公开(公告)日:2010-08-05
    2'-0-substituted 14- or 15-membered azalide macrolides of Formula (I) wherein R6 represents (i) -C1-8alkyl, unsubstituted or substituted at the terminal carbon atom by a group selected from hydroxy, -C1-3alkoxy and -C(O)OC1-3alkyl, or when -C1-8alkyl is branched, substitution can alternatively be by a hydroxyl group at each of two terminal carbon atoms, (ii) -CH(NH2)C1-4alkyl, wherein the -C1-4alkyl group may be optionally interrupted by a heteroatom selected from O, S and N, (iii) -CH2N(R7)(R8), wherein R7 and R8 each independently represent H or -C1-3alkyl provided that R7 and R8 cannot both simultaneously represent H, (iv) a 4-6-membered heterocyclic ring containing up to 2 heteroatoms independently selected from O, S and N, wherein the heterocyclic ring is unsubstituted or substituted by -C1-3alkyl, (v) 5-6 membered heteroaromatic ring, unsubstituted or substituted by one to three groups independently selected from halo, hydroxyl, -C1-3alkyl, -C1-3alkoxy, -CF3, -OCF3 and -NH2, (vi) -CH(NH2)CH2-aryl wherein the aryl group may be unsubstituted or substituted by one or two substituents independently selected from -C1-3alkyl, -C1-3alkoxy and hydroxyl, (vii) -C3-7cycloalkyl, or (viii) phenyl unsubstituted or substituted by one or two groups independently selected from halo, hydroxyl, -C1-3alkyl, -C1-3alkoxy, -CF3, -OCF3 and -NH2, or salts thereof, useful in the treatment of neutrophil dominated inflammatory diseases, especially in the treatment of neutrophil dominated inflammatory diseases resulting from neutrophilic infiltration and/or diseases associated with altered cellular functionality of neutrophils, to methods for their preparation, to their use as therapeutic agents, and to salts thereof.
    式(I)中的2'-0-取代的14-或15-成员氮杂环巨环内酮类化合物,其中R6代表(i)-C1-8烷基,未取代或在末端碳原子处被羟基、-C1-3烷氧基和-C(O)OC1-3烷基中的一种选择的基团取代,或者当-C1-8烷基是支链时,替代可以选择性地由两个末端碳原子的每个都带有一个羟基基团,(ii)-CH(NH2)C1-4烷基,其中-C1-4烷基基团可以选择性地被O、S和N中选择的杂原子中断,(iii)-CH2N(R7)(R8),其中R7和R8各自独立地代表H或-C1-3烷基,前提是R7和R8不能同时代表H,(iv)含有最多2个O、S和N中选择的杂原子的4-6成员杂环,其中该杂环未取代或被-C1-3烷基取代,(v)5-6成员杂芳环,未取代或被一个到三个独立选择的卤素、羟基、-C1-3烷基、-C1-3烷氧基、-CF3、-OCF3和-NH2基团取代,(vi)-CH(NH2)CH2-芳基,其中芳基可以未取代或被一个或两个独立选择的-C1-3烷基、-C1-3烷氧基和羟基取代,(vii)-C3-7环烷基,或(viii)苯基未取代或被一个或两个独立选择的卤素、羟基、-C1-3烷基、-C1-3烷氧基、-CF3、-OCF3和-NH2基团取代,或其盐,用于治疗中性粒细胞主导的炎症性疾病,特别是用于治疗由中性粒细胞浸润引起的中性粒细胞主导的炎症性疾病和/或与中性粒细胞功能改变相关的疾病,以及它们的制备方法,作为治疗剂的使用以及其盐。
  • Compounds
    申请人:Alihodzic Sulejman
    公开号:US20110281812A1
    公开(公告)日:2011-11-17
    2′-O-substituted 14- or 15-membered azalide macrolides of Formula (I) wherein R 6 represents (i) —C 1-8 alkyl, unsubstituted or substituted at the terminal carbon atom by a group selected from hydroxy, —C 1-3 alkoxy and —C(O)OC 1-3 alkyl, or when —C 1-8 alkyl is branched, substitution can alternatively be by a hydroxyl group at each of two terminal carbon atoms, (ii) —CH(NH 2 )C 1-4 alkyl, wherein the —C 1-4 alkyl group may be optionally interrupted by a heteroatom selected from O, S and N, (iii) —CH 2 N(R 7 )(R 8 ), wherein R 7 and R 8 each independently represent H or —C 1-3 alkyl provided that R 7 and R 8 cannot both simultaneously represent H, (iv) a 4-6-membered heterocyclic ring containing up to 2 heteroatoms independently selected from O, S and N, wherein the heterocyclic ring is unsubstituted or substituted by —C 1-3 alkyl, (v) 5-6 membered heteroaromatic ring, unsubstituted or substituted by one to three groups independently selected from halo, hydroxyl, —C 1-3 alkyl, —C 1-3 alkoxy, —CF 3 , —OCF 3 and —NH 2 , (vi) —CH(NH 2 )CH 2 -aryl wherein the aryl group may be unsubstituted or substituted by one or two substituents independently selected from —C 1-3 alkyl, —C 1-3 alkoxy and hydroxyl, (vii) —C 3-7 cycloalkyl, or (viii) phenyl unsubstituted or substituted by one or two groups independently selected from halo, hydroxyl, —C 1-3 alkyl, —C 1-3 alkoxy, —CF 3 , —OCF 3 and —NH 2 , or salts thereof, useful in the treatment of neutrophil dominated inflammatory diseases, especially in the treatment of neutrophil dominated inflammatory diseases resulting from neutrophilic infiltration and/or diseases associated with altered cellular functionality of neutrophils, to methods for their preparation, to their use as therapeutic agents, and to salts thereof.
  • Around the macrolide – Impact of 3D structure of macrocycles on lipophilicity and cellular accumulation
    作者:Sanja Koštrun、Vesna Munic Kos、Maja Matanović Škugor、Ivana Palej Jakopović、Ivica Malnar、Snježana Dragojević、Jovica Ralić、Sulejman Alihodžić
    DOI:10.1016/j.ejmech.2017.03.056
    日期:2017.6
    the molecular level. The effect of substitution site and substituent properties on a global physico-chemical profile and cellular accumulation of investigated compounds was studied using calculated structural parameters as well as experimentally determined lipophilicity. In silico models based on the 3D structure of molecules were generated to investigate conformational effect on studied properties and
    这项研究的目的是在分子水平上研究合理设计的阿奇霉素和克拉霉素衍生物的亲脂性和细胞蓄积性。使用计算的结构参数以及实验确定的亲脂性,研究了取代位点和取代基性质对所研究化合物的整体物理化学特征和细胞积累的影响。在基于分子3D结构的计算机模型中,研究了构象效应对所研究性质的影响,并基于非经验参数预测了此类分子的亲脂性和细胞蓄积性。在验证和测试集上探索了开发模型的适用性,并与先前开发的经验模型进行了比较。
查看更多